MTOR and colonic neoplasm: We evaluated the impact of the allosteric (rapamycin) and two catalytic mTOR inhibitors (AZD8055, AZD2014) on the survival of four colon cancer cell lines, characterized by specific mutations, leading to activated Ras/MAPK and PI3K signaling pathways (Table S1).